Spero Therapeutics (STU:2HA) EV-to-EBIT : 0.71 (As of May. 12, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Spero Therapeutics's Enterprise Value is €16.32 Mil. Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €22.98 Mil. Therefore, Spero Therapeutics's EV-to-EBIT for today is 0.71.

The historical rank and industry rank for Spero Therapeutics's EV-to-EBIT or its related term are showing as below:

STU:2HA' s EV-to-EBIT Range Over the Past 10 Years
Min: -57.34 Med: -1.85 Max: 1.03
Current: 0.69

During the past 9 years, the highest EV-to-EBIT of Spero Therapeutics was 1.03. The lowest was -57.34. And the median was -1.85.

STU:2HA's EV-to-EBIT is ranked better than
69.05% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs STU:2HA: 0.69

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Spero Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €3.51 Mil. Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €22.98 Mil. Spero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 654.93%.

Spero Therapeutics EV-to-EBIT Historical Data

The historical data trend for Spero Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics EV-to-EBIT Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-1.71

-5.73

-4.32

0.27

0.28

Spero Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															0.27	0.51	-0.46	-39.97	0.28

Competitive Comparison of Spero Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Spero Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's EV-to-EBIT falls into.

Spero Therapeutics EV-to-EBIT Calculation

Spero Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	16.321	/	22.979
	=	0.71

Spero Therapeutics's current Enterprise Value is €16.32 Mil.
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.98 Mil.

Spero Therapeutics (STU:2HA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Spero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	22.979	/	3.5086127
	=	654.93 %

Spero Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €3.51 Mil.
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.98 Mil.

Spero Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines